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Evaluation of microbubble contrast 
agents for dynamic imaging with 
x-ray phase contrast
T. P. Millard1, M. Endrizzi1, N. Everdell1, L. Rigon2,3, F. Arfelli2,3, R. H. Menk4, E. Stride5 & 
A. Olivo1
X-rays are commonly used as a means to image the inside of objects opaque to visible light, as their 
short wavelength allows penetration through matter and the formation of high spatial resolution 
images. This physical effect has found particular importance in medicine where x-ray based imaging is 
routinely used as a diagnostic tool. Increasingly, however, imaging modalities that provide functional 
as well as morphological information are required. In this study the potential to use x-ray phase 
based imaging as a functional modality through the use of microbubbles that can be targeted to 
specific biological processes is explored. We show that the concentration of a microbubble suspension 
can be monitored quantitatively whilst in flow using x-ray phase contrast imaging. This could provide 
the basis for a dynamic imaging technique that combines the tissue penetration, spatial resolution, 
and high contrast of x-ray phase based imaging with the functional information offered by targeted 
imaging modalities.
Advances in medicine are increasingly directed towards targeted interventions and disease specific ther-
apies, with the aim of maximising the benefit to risk ratio for individual patients1. Not only does this 
require detailed understanding of specific disease pathways, to develop effective targeting strategies, but 
also imaging modalities that enable visualisation of these processes for both diagnosis and treatment 
monitoring.
Imaging modalities which could be used for this type of functional imaging include nuclear imaging, 
magnetic resonance imaging (MRI), ultrasound and x-ray based imaging. In each case disease specific 
information is provided through the use of a contrast agent functionalised to target the relevant tissue 
process or biomarker2. Currently, the nuclear imaging techniques of single-photon emission computed 
tomography (SPECT), and positron emission tomography (PET), are used routinely for clinical func-
tional imaging.
X-ray imaging offers excellent spatial and temporal resolution, tissue penetration, and is routinely 
used clinically for diagnostic and, as part of, therapeutic procedures. If functional information could 
be gained directly from an x-ray based image, then this could be of benefit to a wide range of clinical 
applications.
X-ray images are conventionally acquired based on the principle of absorption, whereby the x-ray 
shadow of an object is recorded. A major limitation of conventional x-ray based imaging is that it offers 
relatively poor soft tissue contrast, particularly compared with MRI. Recent developments based on the 
use of phase in x-ray imaging have however addressed this. The new techniques instead exploit the phase 
shift of the x-ray wave front. For clinically relevant materials and energies this is an effect approximately 
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three orders of magnitude larger than absorption3, meaning that soft tissue can be imaged at high spatial 
resolution (<100 μ m) with excellent contrast. Phase based methods have also been demonstrated for 
CT4, tomosynthesis6 and real time imaging5 (fluoroscopy).
Molecular absorption based x-ray imaging has been demonstrated using targeted nanoparticles con-
taining iodine7, and more recently gold8,9. An energy resolving detector can also be used to provide some 
differentiation between tissue and contrast agent10,11. An x-ray phase based method would build on this 
through the greater sensitivity it provides, and the potential for utilising more biocompatible contrast 
agents.
Microbubbles have been shown to be effective molecular probes for ultrasound imaging12–14. They 
consist of a gas core surrounded by a surfactant or polymer shell, whose surface can be functionalised 
with a range of targeting species. Microbubbles can also be used as vehicles to deliver therapeutic agents15 
(either encapsulated or embedded in the shell) enabling both controlled release and enhanced cell uptake 
of the therapeutic agent through a process termed sonoporation16,17.
An individual microbubble refracts x-rays acting as an x-ray lens. A population of microbubbles 
therefore acts to scatter x-rays as a consequence of multiple refraction in many directions. This generates 
an area contrast when imaged using an XPCi system sensitive to ultra small angle scatter. It has previ-
ously been shown that microbubbles are an effective x-ray phase based contrast agent18, with contrast 
enhancement shown with a laboratory x-ray source19 as well as with synchrotron based methods20.
For effective functional imaging, it is necessary to be able to monitor and ideally quantify, the concen-
tration of a probe within a given region of interest as a function of time. In this study we demonstrate 
that microbubble concentration can be tracked in real time using x-ray phase contrast imaging (XPCi) 
under physiologically relevant flow conditions. This development offers the possibility of using XPCi 
as a modality for dynamic functional imaging of microbubbles, enabling quantification of microbubble 
concentration in a given volume whilst also providing the required high spatial and temporal resolution, 
imaging depth and soft tissue contrast. A functional imaging approach based on XPCi has the advantage 
that a single modality can be used for both high resolution imaging of soft tissue and bone, whilst also 
providing functional information through the dark field image it makes available21,22.
Results
The results presented below demonstrate that a changing microbubble concentration can be tracked 
quantitatively whilst in flow through a vessel phantom using XPCi. We have previously shown that static 
microbubble concentrations can be quantified using a ‘single-shot’ XPCi dark field method, whereby 
microbubbles were imaged in cuboid shaped containers23. Images were taken using an analyser crystal 
based XPCi approach, which is a method that can be extended to other XPCi approaches24. A single-shot 
dark field image refers to an image taken with the majority of the primary beam excluded so that the 
imaging system is primarily sensitive to x-rays which have undergone ultra-small angle scattering.
A functional XPCi method using microbubbles would be based on imaging the localisation of tar-
geted microbubbles injected into the circulatory system. Monitoring of targeted drug delivery would then 
be a natural extension of this by embedding a therapeutic agent within the microbubbles.
To demonstrate this we show that a varying concentration of microbubbles flowing through a tube 
(with 4 mm internal diameter to model a vessel, see Fig. 1c) can be extracted from a sequence of x-ray 
dark field images. Images were continuously acquired as the flowing microbubble concentration was 
reduced in a controlled manner using a custom designed flow phantom (Fig. 1b–e). For this experimen-
tal run the pump flow rate was set to 80 ml/min, and the microbubble concentration decay constant D 
(see equation 1) was 0.056 s−1. A video of this result is shown in supplementary material 1, with Fig. 1a 
containing a selection of frames from the sequence. The microbubbles make the centre of the tube appear 
bright in the first frame (taken at 0 seconds). Over time, as the microbubble concentration reduces, the 
signal intensity produced by the microbubbles also decreases.
Three image sequences were then collected with a different microbubble concentration decay constant 
(D) set using a pinch valve, but with the flow rate of liquid through the pump kept constant (250 ml/min). 
The average intensity in the pixels of the central region of the tube was found for each frame, with the 
result for each image sequence plotted against time. It proved difficult to achieve precisely the same initial 
starting concentration for each run, and so zero seconds (t = 0) in Fig. 2 is set to a point at which the 
signal intensity for all three runs overlap. Previous results23 demonstrate that this corresponds to identical 
microbubble concentrations in the tube.
The result of this is shown in Fig. 2, which shows that the rate of decrease in microbubble concen-
tration is related to the rate of decrease in detected intensity. The sequence for which the decrease in 
microbubble concentration is fastest also shows the fastest decrease in detected intensity. This is expected 
as the microbubbles generate the signal, and so a faster decrease in concentration leads to faster decay 
in detected intensity.
It can be seen that, in all three cases, the intensity decays to the same (non-zero) level, due to some 
residual absorption signal which is also detected when using this single-shot method23. When the con-
centration of microbubbles flowing through the tube becomes close to zero, the intensity detected in all 
three cases tends to the same asymptotic value.
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A Monte Carlo simulation was used to model the signal intensity generated by different concentra-
tions of microbubbles in the tube. The simulation of samples of known microbubble concentration using 
the previously validated simulation then provides benchmark data23.
For each run the microbubble decay constant is known from calibration of the experimental appa-
ratus. Equations 1 and 2 were then used to calculate the microbubble concentration within the tube 
Figure 1. (a) Stacked sequence of images taken whilst the microbubble concentration flowing through the 
tube was reduced. Time (s) elapsed from valve opening is indicated on the left of the figure for each frame 
in seconds, with all frames displayed using the same grayscale. (b) Diagram of the experimental set-up 
showing the x-ray beam incident on the tubing. (c) Diagram depicting how microbubbles were imaged while 
flowing through the tubing. (d) Schematic of the microbubble flow phantom showing the region imaged, the 
inlet and outlet, and the volumes Vl and Vp. (e) Photograph of the microbubble flow device installed at the 
SYRMEP beamline at the ELETTRA synchrotron (Italy).
Figure 2. Average intensity calculated in a central region of the tube from three image sequences taken 
with a different microbubble concentration decay constant (D) for each. 
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for each sequence image. This allows a plot of detected intensity against microbubble concentration to 
be produced, as shown in Fig. 3a. This provides a direct quantitative link between signal intensity and 
microbubble concentration allowing the latter to be estimated from the former.
Figure  3a contains the simulated benchmark data, as well as the data from Fig.  2 where time has 
been converted to microbubble volume concentration. It can be seen that all cases show the same trend 
between intensity and microbubble concentration.
A subtraction method was then used, whereby an image of the tube with a zero concentration of 
microbubbles (referred to from here as the background intensity) was subtracted from each sequence 
image, with the results plotted in Fig.  3b. It can be seen that, as a result of this simple correction, 
zero intensity corresponds to zero microbubble concentration, with the same trend seen as before with 
increasing concentration.
To give an idea of the sensitivity of such a system to microbubble concentration the signal to noise 
ratio was calculated for the experimental data shown in Fig. 3b. The Rose criterion states that a signal 
to noise ratio of five is needed to distinguish a detail25. For the experimental data shown in Fig. 3b this 
corresponds to a microbubble concentration of 0.0017. This value should be treated as a ballpark figure 
Figure 3. Plots demonstrating how signal intensity is related to microbubble concentration, (a) contains 
data from Fig. 2 where time has been converted to microbubble concentration, and (b) the result of 
subtracting the background intensity. (c) Shows the result of a linear fit to the experimental data in (b).  
(d) A plot of the residual of the experimental data and fit shown in Fig. 3c, to show the non-linearity of the 
system response. Markers are the residual, with the line depicting a perfect agreement between experiment 
and fit.
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as the system used was synchrotron based, and may not relate to that which could be achieved using a 
conventional x-ray source. It should also be seen in the context of our simplified phantom structure, and 
the ‘structural’ noise in a real patient that would make detection more difficult.
It appears as if intensity and microbubble concentration have an approximately linear relationship. 
Figure 3c contains a plot of the experimental data from Fig. 3b with its corresponding linear fit. A plot 
of the residuals (Fig. 3d) demonstrates that this is not an exact representation of the trend. However, to 
a first approximation, this result suggests that for the range of microbubble concentrations used, a linear 
relation could make the estimation of microbubble concentration more straightforward.
Discussion
It has been shown that using an XPCi method a changing microbubble concentration can be dynam-
ically tracked in a quantitative manner, which could provide a basis for a functional XPCi technique. 
As a future development this may allow for XPCi to be used to localise microbubbles targeted towards 
biological markers, and to measure the concentration of microbubbles at these locations. As well as 
having use for functional imaging, such an approach could also be used as a means to monitor targeted 
microbubble therapies. For this technique to be appropriate for clinical applications a number of further 
technical challenges will need to be addressed.
The experimental results discussed use a single 4 mm internal diameter tube which corresponds, for 
example, to the diameter of an adult human coronary artery26. For use in-vivo it can be envisaged that it 
would be desirable to image vessels of smaller diameter, for which further investigation is required. The 
sensitivity to microbubble concentration and vessel diameter can be expected to vary greatly depending 
on the XPCi system used. An investigation of the sensitivity of XPCi signal with varying tube diameter 
will therefore first require a detailed study of the optimum XPCi system for this application.
A synchrotron based analyser crystal XPCi method was used for the work here, as this method has 
been well studied and used previously for microbubble imaging18,20,23. An analyser based approach can 
be used with a conventional x-ray tube source27,28, but it may not be the most appropriate choice in a 
clinical scenario. Grating interferometry and edge illumination also both allow dark field imaging, and 
these three methods need to be studied to find which is best suited22,29. Potential limitations which need 
to be studied are sensitivity, exposure time, radiation dose, field of view, system size, and the tolerance 
of the system to vibration.
Results presented here have been based on planar imaging, and it may be noted that the vessel cross 
section is needed. This could be solved by using an image processing approach to calculate the cross 
section of the cylindrical vessels from a projection. It should also be possible to extend the method to 
a true 3D modality such as a stereographic, tomographic or CT based approach as 3D methods have 
previously been demonstrated with XPCi4.
Further study is also required ex-vivo using microbubbles appropriate for clinical use. Here Expancel© 
(AkzoNobel, Netherlands) microbubbles were used as their polymer shell gave them the stability required 
for the experiment. Microbubbles were needed which did not burst to allow accurate calculations of 
microbubble concentration. Signal intensity would be expected to have a dependence on the microbub-
ble size distribution, and so microbubble formulations of different size distributions would be expected 
to have different relationships with signal intensity. Microbubbles used as an ultrasound contrast agent 
are required to oscillate to amplify the signal but in XPCi, as this is not needed, microbubbles could be 
designed with shells of increased rigidity. The microbubble formulation itself could therefore also be 
optimised to maximise the XPCi signal.
As well as this, investigations are needed to find how targeting agents on a microbubble shell (for 
example antibodies or magnetic particles30) affect the detected intensity. It could be envisaged that the 
ultra-small angle scatter signal could actually be amplified by nanoparticles embedded in a microbubbles 
shell, through increased x-ray scatter from these. Nanoparticles have been proposed in combination with 
microbubbles as a means for targeted drug delivery31,32 and, though not studied here, since nanoparticles 
produce an ultra-small angle scatter signal, XPCi could also potentially be used to monitor the concen-
tration of these.
The method proposed has the potential to be used for a diverse range of clinical applications, with 
the possibilities limited only by the range of biological markers towards which microbubbles can be 
targeted33. The results presented here demonstrate the quantitative measurement of microbubble concen-
tration using XPCi which provides a basis for the development of functional x-ray imaging modalities.
Methods
X-ray Phase Contrast Imaging (XPCi). Samples were imaged using the analyser based imaging 
(ABI) XPCi method at the SYRMEP beamline of the ELETTRA synchrotron facility (Trieste, Italy)34,35. 
An energy of 17 keV was selected by a Si(1 1 1) double-crystal monochromator, with a double crystal 
analyser arrangement obtained using two single flat Si(1 1 1) crystals. The analyser crystals are placed 
between sample and detector to convert the phase shifts introduced by the object into a measurable inten-
sity. Images were recorded using a CCD camera with a 9 μ m pixel size (Photonic Science, Robertsbridge, 
UK). The crystal rocking curve position was measured as the fraction of the readings of ionisation cham-
bers placed either side of the analyser crystals to give the crystal reflectivity.
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All image sequences were acquired using the single-shot dark field method23, with the analyser crys-
tal positioned at the tail of the crystal rocking curve so that 5% crystal reflectivity is seen. Images were 
acquired with a 0.5 second exposure time, with 4 × 4 detector binning used to decrease read out time. In 
this mode the detector had a read out time of 0.27 seconds, which gave a frame rate of 0.77 seconds. In 
all cases intensity was averaged from a region in the centre of the tube.
Sample Preparation. For this proof of principle work microbubbles were required which are stable 
for a sufficiently long period. Polymer shell Expancel (AkzoNobel) microbubbles were used, which 
have a copolymer shell of acrylonitrile and vinylidene chloride and a median radius of 4 μ m.
Flowing microbubbles were imaged in ultrasound coupling gel (Anagel, Ana Wiz Ltd., Surrey, UK), 
which predominately consists of water with propylene glycol and glycerol. The gel was diluted to lower 
the viscosity and allow for pumping and mixing of the flowing liquid. This was prepared by mixing one 
part ultrasound coupling gel to four parts water, with this ratio chosen as it was found experimentally 
to be viscous enough to allow for a homogeneous distribution of microbubbles in the flow device, whilst 
also allowing for mixing during the flow devices dilution action. In-vivo microbubbles would be imaged 
flowing in the circulatory system, where they will be held in suspension in blood. It should be noted that 
blood is more viscous than water, and this gel solution was designed with this in mind.
An experiment was performed where the gel was imaged in water using the same experimental set-up, 
which showed that the gel was indistinguishable from water.
Flow Device. The experimental apparatus used was custom designed for this experiment as a means 
of flowing microbubbles at physiologically relevant flow rates through the imaged section of tubing. The 
device (shown in Fig. 1e) also made it possible to dynamically decrease the concentration of the flowing 
microbubbles.
The device consists of a series 200 mini peristaltic pump fitted with 5 mm internal diameter silicone 
tubing and powered by a stepper motor (Williamson Pumps Ltd, Poynings, UK) which allowed for 
accurate control of flow rates up to 250 ml/min. A loop of tubing was then created between the inlet 
and outlet of the pump, with a part of this being the 4 mm internal diameter Nylon-12 tubing through 
which the microbubble containing liquid was imaged. Nylon-12 was chosen as it produces a minimal 
ultra-small angle scatter signal and similar x-ray attenuation to water.
At the two junctions between pump inlet/outlet and the loop tubing a further two pieces of tub-
ing were connected, which function as an input and output to the loop. A solenoid pinch valve (Sirai, 
Bussero, Italy) was located on each of these, close to the loop, which allows for the input/output of the 
loop to be opened/closed. The loop is filled with a high microbubble concentration liquid, which is then 
pumped around the loop at the desired flow rate with the valves closed. A container of liquid without 
microbubbles is placed on the input tubing, and the valves opened. The differential pressure between the 
pump inlet and outlet results in this microbubble free liquid being drawn into the loop, thus decreasing 
the flowing microbubble concentration. This rate of dilution is continuous, and can be accurately con-
trolled by pump flow rate and changing the diameter of the input tubing using a pinch valve. A schematic 
of this system is shown in Fig. 1d.
The system was controlled via a data acquisition (DAQ) device (NI USB-6008) and LabVIEW soft-
ware (National Instruments, Texas, US).
When the valves are opened the microbubble concentration flowing through the loop decreases at an 
approximately exponential rate. This assumption can be made as the length of the loop tubing is short 
relative to the combination of pump flow rate and detector exposure time. If the initial concentration 
flowing around the loop is C1, and the concentration after time t is Ct then
= ( )−C C e 1t
tD
1
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Here Q is the pump flow rate (ml/s), Vp is the volume of loop tubing on the pump side of the loop 
junction (2.3 ml) and Vl on the opposite side of the loop junction (2.8 ml). R is the flow rate through the 
output tube divided by the flow rate through the pump.
Simulation. The computational model used to simulate microbubble XPCi was a Monte Carlo model 
developed using McXtrace36, which we previously validated for microbubbles23.
Using the experimentally measured size distribution, 3D numerical microbubble phantoms were cre-
ated with a range of concentrations. These numerical phantoms consisted of a random 3D arrangement 
of polydisperse spheres within a hollow cylinder with wall thickness to match the Nylon-12 tubing. The 
real and imaginary components of the refractive index for each material were taken from xraylib37, with 
materials Nylon-12 and water used to model the tube wall and liquid within the cylinder respectively.
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The simulation was performed as follows. A parallel plane wave of 17 keV photons was incident on 
the numerical phantom. These pass through the sample, being attenuated and deflected at boundaries 
according to the principles of ray optics. Directly after the sample the direction of the wave is finely 
sampled, with this then convolved with the experimentally measured analyser crystal rocking curve. The 
signal at a crystal rocking curve position can then be found on a pixel by pixel basis from this result.
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